Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161173 | 0.88 | HSD17B2 (0.66) | HSD17B2MAPTMEN1KMT2AGAA | |
| SCHEMBL30036339 | 0.86 | MAPT (0.57) | MAPTMEN1KMT2ASMN1; SMN2CA12 | |
| SCHEMBL854310 | 0.86 | MAPT (0.57) | MAPTMEN1KMT2ASMN1; SMN2CA12 | |
| SCHEMBL1351357 | 0.85 | HSD17B2 (0.61) | HSD17B2MAPTMEN1KMT2AGAA | |
| SCHEMBL31094175 | 0.84 | CA12 (0.57) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL6160950 | 0.84 | CA12 (0.57) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL18502198 | 0.83 | CA12 (0.56) | HSD17B2MAPTMEN1KMT2ANPC1 | |
| SCHEMBL1660365 | 0.82 | HSD17B2 (0.76) | HSD17B2MAPTMEN1KMT2AGAA | |
| SCHEMBL30506315 | 0.82 | HSD17B2 (0.76) | HSD17B2MAPTMEN1KMT2AGAA | |
| SCHEMBL137329 | 0.81 | CA12 (0.54) | HSD17B2MAPTMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| CN-108430515-B | Antibody conjugates comprising TOLL-like receptor agonists | 诺华股份有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| EP-3137468-B1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3873532-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2021-09-08 | — | — | EP | disclosed |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3797797-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3797797-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| US-10844068-B2 | Compounds and compositions as toll-like receptor 7 agonists | NOVARTIS AG (CH) | 2020-11-24 | — | — | US | disclosed |
| EP-3368092-B9 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3137468-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | Novartis AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| US-20170044168-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170044168-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015168279-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168279-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
| US-7189741-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2007-03-13 | — | — | US | disclosed |
| EP-1330453-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-03-29 | — | — | EP | disclosed |
| US-20040116471-A1 | Indolylpiperidine derivatives as antihistaminic aand antiallergic agents | ALMIRALL PRODESFARMA S.A. (ES) | 2004-06-17 | — | — | US | disclosed |
| EP-1330453-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036589-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | DCUN1D4, CD14, DCUN1D3 | HSD17B2 4308/4885MAPT 1439/4885MEN1 2029/4885 |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | HSD17B2 4566/4885MAPT 2635/4885MEN1 4575/4885 |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | TLR3, TLR2, TLR9 | HSD17B2 4566/4885MAPT 2635/4885MEN1 4575/4885 |
| US-10844068-B2 | Compounds and compositions as toll-like receptor 7 agonists | TLR7, TLR3, TLR1 | HSD17B2 3299/4885MAPT 3066/4885MEN1 4332/4885 |
| US-20170044168-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | TLR7, TLR3, TLR1 | HSD17B2 4213/4885MAPT 2368/4885MEN1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.